New Product Agreements Complement and Further Enhance Medical Product Offering

BETHESDA, Md., Aug. 10 /PRNewswire-Asia/ -- Chindex International, Inc. ('Chindex') (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that it has entered into two new exclusive, multi-year distribution agreements for China with Biotest AG and Cutera Inc.

Biotest AG, based in Dreieich, Germany (SDAX: BIO3), specializes in innovative hematology and immunology products. Biotest has appointed Chindex as the exclusive distributor for its unique Tango Optimo Automated Blood Bank System for the People's Republic of China. The Tango Optimo automates all routine testing procedures performed in blood banking, including blood grouping, antibody screening, and cross matching, and is the only blood bank analyzer that offers seven-day on-board storage of liquid and microplate reagents. Upon receipt of regulatory approval from China's State Food and Drug Administration, Chindex will market the Tango Optimo to hospital laboratories along with the Johnson & Johnson Ortho Clinical Diagnostics line of clinical chemistry analyzers.

Cutera Inc. (Nasdaq: CUTR) is a leading manufacturer of upgradeable, easy-to-use laser and other light-based aesthetic systems used by physicians and other qualified practitioners worldwide. Under the terms of the agreement, Chindex will market and distribute the upgradeable Xeo, Solera, and CoolGlide platforms in China and Hong Kong. The Cutera family of lasers, several of which have already been registered with the Chinese State Food and Drug Administration, provides an excellent complement to present Chindex product line.

Roberta Lipson, Chindex President and CEO, commented from Beijing, 'We are excited to be announcing these partnerships with industry-leading manufacturers that will widen the breadth of products that Chindex can now offer to China's healthcare communities. Importantly, both of these exclusive agreements leverage our existing leadership in their respective target markets in China.